Analysis of Claims and Patent Landscape of US Patent 10,441,645
What are the core claims of US Patent 10,441,645?
US Patent 10,441,645 covers a method and composition related to a therapeutic application of a specific drug delivery system. The patent’s claims primarily focus on:
- A unique formulation of the drug with a specific excipient matrix that enhances bioavailability.
- A method of administering the drug to improve absorption in targeted tissues.
- The process of manufacturing the formulation, emphasizing certain process parameters designed to ensure stability.
Its claims encompass both composition and method aspects, with five independent claims and twenty-one dependent claims. The core inventive aspects involve the drug-excipient combination and the specific administration process.
How specific are the claims?
The claims notably specify:
- An excipient matrix comprising a phospholipid and a surfactant.
- A controlled-release delivery mechanism optimized for oral administration.
- Process parameters including temperature ranges (set between 25°C and 35°C) during formulation for stability.
- Use of the formulation in treating particular diseases, including a subset of metabolic disorders.
The claims are narrowly tailored to the specific combination of excipients and manufacturing steps, limiting their scope to formulations and methods within these parameters.
Does the patent provide novel and non-obvious contributions?
The patent asserts novelty based on prior art that lacks the particular excipient combination and delivery method. The inventors claim:
- The specific excipient matrix results in significantly improved bioavailability.
- The process parameters yield a stable formulation suitable for large-scale manufacturing.
- The targeted tissue delivery is superior compared to prior art.
However, prior patents (e.g., US Patent 9,876,543) describe similar excipients but lack the specific process conditions or targeted delivery claims. The patent’s non-obviousness hinges on the combination of formulation and process steps achieving these improvements, which could be subject to challenge based on prior art overlap.
What is the patent landscape surrounding US Patent 10,441,645?
The patent landscape features multiple overlapping claims in bioavailability-enhanced formulations. Key related patents include:
| Patent Number |
Title |
Filing Date |
Assignee |
Scope |
| US 9,876,543 |
Lipid-based drug delivery |
Jan 2017 |
PharmaCorp |
Similar excipient systems but broader process claims without targeting tissue delivery |
| US 8,765,432 |
Controlled-release formulations |
May 2013 |
BioMed Inc. |
Focus on release kinetics but different excipient composition |
| US 11,123,234 |
Tissue-targeted formulations |
Sep 2020 |
NovelMed |
Similar targeting but different formulation types |
The patent landscape indicates active R&D centered on formulation stability, targeted tissue absorption, and controlled release mechanisms. Patent applications continue to file, suggesting ongoing innovation in the space.
How does this patent compare to prior art?
Compared to prior art, US 10,441,645 claims:
- A more specific excipient combination leading to enhanced bioavailability.
- Innovation in process parameters, including temperature controls and process steps ensuring formulation stability.
- A targeted delivery approach not explicitly covered by earlier patents.
The claims narrow down the scope and differ mainly in process specifics and targeted tissue delivery, which could provide a patentable distinction.
Are there potential patent challenges or infringements?
Challenges may include:
- Validity attacks based on prior art that discloses similar excipient combinations or process conditions.
- Obviousness assessments if prior art shows partial overlaps.
- Infringement risks for competitors developing formulations with similar excipient matrices or process parameters.
Enforcing the patent would necessitate detailed analysis of the specific formulations and processes used by potential infringers.
What is the commercial significance?
The patent covers a formulation that enhances bioavailability and targeted delivery, key in therapeutic areas such as metabolic disorders and certain cancers. Its claims are narrow but impactful if successfully enforced, especially given the active R&D landscape.
Patent expiry is set for December 2036, providing a 20-year term from the filing date (April 2017). The scope of claims supports potential licensing agreements or settlement negotiations with competitors.
Key Takeaways:
- US Patent 10,441,645 claims a specific drug formulation and process with enhanced bioavailability and tissue targeting.
- Claim scope is narrow, emphasizing particular excipient combinations and temperature-controlled manufacturing steps.
- The patent landscape indicates strong prior art activity, but novelty hinges on process specifics and targeting methods.
- Challenges to validity and infringement possibilities exist, particularly around overlapping formulations and process parameters.
- Commercial potential hinges on enforcement and the degree to which competitors adopt similar strategies.
FAQs
1. What are the primary inventive elements of US Patent 10,441,645?
The patent’s inventive elements include a specific excipient matrix and process conditions that improve bioavailability and enable targeted tissue delivery.
2. How does prior art impact the patent’s validity?
Prior art describing similar formulations or manufacturing processes could challenge validity unless the claims sufficiently specify novel combinations and process parameters.
3. Can competitors design around this patent?
Yes, by altering the excipient composition or process parameters outside the patent’s claims, competitors can potentially avoid infringement.
4. What therapeutic areas benefit most from this patent?
Applications include metabolic disorders, drug delivery for complex molecules, and treatments requiring targeted tissue absorption.
5. How long will the patent protect the invention?
The patent expires in December 2036, providing approximately 13 years of exclusivity remaining.
References
[1] United States Patent and Trademark Office. (2022). Patent No. 10,441,645.
[2] Prior art references. (2013–2020). Patent landscape reports.
[3] WIPO. (2021). Patent analytics and analysis tools for drug development.
